Beyond Biotech podcast 47 By Jim Cornall 1 minutemin May 26, 2023 -Updated: onMay 23, 2024 1 minutemin Share WhatsApp Twitter Linkedin Email Photo/Shutterstock Newsletter Signup - Under Article / In Page"*" indicates required fieldsCompanyThis field is for validation purposes and should be left unchanged.Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*Company name*Job title*Business email* The companies Daiichi Sankyo and AstraZeneca have worked together for several years.This week’s podcast is sponsored by Daiichi Sankyo and AstraZeneca.On this week’s podcast, we have a conversation with Markus Kosch, the head of Oncology Europe and Canada for Daiichi Sankyo, and Greg Rossi, Senior Vice President, Oncology, Europe and Canada, from AstraZeneca, who are joining forces to bring new oncology medicines into clinical practice.In March 2019, AstraZeneca and Daiichi Sankyo entered into a global collaboration to jointly develop and commercialize health technologies worldwide. Their collaboration is designed to leverage strengths and combine efforts to improve patient care.Organoids in cancer research: Paving the way for faster drug development across cancer indications This webinar explores how patient-derived organoids (PDOs) are redefining oncology research. Discover how advanced, well-characterized models empower researchers to streamline candidate selection, accelerate orphan drug programs, and deliver transformative therapies to patients faster than ever. Watch now Explore other topics: AstraZenecaCancerDaiichi SankyoPartnerships ADVERTISEMENT